FFO
KPTI icon

Fortitude Family Office’s Karyopharm Therapeutics KPTI Stock Holding History

Fortitude Family Office’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-81
Closed -$530 – 2031
2025
Q3 		$530 Hold
81
– – ﹤0.01% 1784
2025
Q2 		$349 Buy
+81
New +$397 ﹤0.01% 1902

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Fortitude Family Office's KPTI Position: Q4 2025 in Review

Fortitude Family Office sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 81 shares — an estimated $530 sold.

Fortitude Family Office first reported a position in KPTI in Q2 2025 and held it in 2 quarters. The position peaked at $530 in Q3 2025. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Fortitude Family Office reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fortitude Family Office sold 81 Karyopharm Therapeutics shares in Q4 2025, an estimated $530.
  • Fortitude Family Office first reported a position in Karyopharm Therapeutics in Q2 2025 and held it in 2 quarters.
  • Fortitude Family Office's Karyopharm Therapeutics position peaked at $530 in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.